0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Anti-Obesity Therapeutics Market Research Report 2023
Published Date: February 2023
|
Report Code: QYRE-Auto-26U13080
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Anti Obesity Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Anti-Obesity Therapeutics Market Research Report 2023

Code: QYRE-Auto-26U13080
Report
February 2023
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global Anti-Obesity Therapeutics Market

Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.
The global Anti-Obesity Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for the drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population were obese in 2014. In developing countries the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-Obesity Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Obesity Therapeutics.
The Anti-Obesity Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Anti-Obesity Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Obesity Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

Key Segmentations

By Company

  • Bristol-Myers Squibb
  • Eisai Company
  • FlaxoSithKline plc.
  • Novo Nordisk
  • Alizyme
  • BoehringerIngelheim GmbH
  • Pfizer
  • Takeda Pharmaceutical
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Vivus
  • Zafgen
  • Norgine Pharmaceuticals Ltd.

Segment by Type

  • Centrally Acting Anti-obesity Drugs
  • Peripherally Acting Anti-obesity Drugs

Segment by Application

  • Hospital Use
  • Clinic Use
  • Household
  • Other

Consumption by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Vietnam
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • U.A.E

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Anti-Obesity Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Anti-Obesity Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

Scope of Global Anti-Obesity Therapeutics Market Report

Report MetricDetails
Report NameGlobal Anti-Obesity Therapeutics Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 Anti-Obesity Therapeutics Market Overview
1.1 Product Overview and Scope of Anti-Obesity Therapeutics
1.2 Anti-Obesity Therapeutics Segment by Type
1.2.1 Global Anti-Obesity Therapeutics Market Value Comparison by Type (2023-2029)
1.2.2 Centrally Acting Anti-obesity Drugs
1.2.3 Peripherally Acting Anti-obesity Drugs
1.3 Anti-Obesity Therapeutics Segment by Application
1.3.1 Global Anti-Obesity Therapeutics Market Value by Application: (2023-2029)
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Global Anti-Obesity Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Anti-Obesity Therapeutics Revenue 2018-2029
1.4.2 Global Anti-Obesity Therapeutics Sales 2018-2029
1.4.3 Global Anti-Obesity Therapeutics Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Anti-Obesity Therapeutics Market Competition by Manufacturers
2.1 Global Anti-Obesity Therapeutics Sales Market Share by Manufacturers (2018-2023)
2.2 Global Anti-Obesity Therapeutics Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Anti-Obesity Therapeutics Average Price by Manufacturers (2018-2023)
2.4 Global Anti-Obesity Therapeutics Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Anti-Obesity Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-Obesity Therapeutics, Product Type & Application
2.7 Anti-Obesity Therapeutics Market Competitive Situation and Trends
2.7.1 Anti-Obesity Therapeutics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-Obesity Therapeutics Players Market Share by Revenue
2.7.3 Global Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Obesity Therapeutics Retrospective Market Scenario by Region
3.1 Global Anti-Obesity Therapeutics Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Anti-Obesity Therapeutics Global Anti-Obesity Therapeutics Sales by Region: 2018-2029
3.2.1 Global Anti-Obesity Therapeutics Sales by Region: 2018-2023
3.2.2 Global Anti-Obesity Therapeutics Sales by Region: 2024-2029
3.3 Global Anti-Obesity Therapeutics Global Anti-Obesity Therapeutics Revenue by Region: 2018-2029
3.3.1 Global Anti-Obesity Therapeutics Revenue by Region: 2018-2023
3.3.2 Global Anti-Obesity Therapeutics Revenue by Region: 2024-2029
3.4 North America Anti-Obesity Therapeutics Market Facts & Figures by Country
3.4.1 North America Anti-Obesity Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Anti-Obesity Therapeutics Sales by Country (2018-2029)
3.4.3 North America Anti-Obesity Therapeutics Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Anti-Obesity Therapeutics Market Facts & Figures by Country
3.5.1 Europe Anti-Obesity Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Anti-Obesity Therapeutics Sales by Country (2018-2029)
3.5.3 Europe Anti-Obesity Therapeutics Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-Obesity Therapeutics Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-Obesity Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Anti-Obesity Therapeutics Sales by Country (2018-2029)
3.6.3 Asia Pacific Anti-Obesity Therapeutics Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Anti-Obesity Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Anti-Obesity Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Anti-Obesity Therapeutics Sales by Country (2018-2029)
3.7.3 Latin America Anti-Obesity Therapeutics Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-Obesity Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-Obesity Therapeutics Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Anti-Obesity Therapeutics Sales by Country (2018-2029)
3.8.3 Middle East and Africa Anti-Obesity Therapeutics Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Anti-Obesity Therapeutics Sales by Type (2018-2029)
4.1.1 Global Anti-Obesity Therapeutics Sales by Type (2018-2023)
4.1.2 Global Anti-Obesity Therapeutics Sales by Type (2024-2029)
4.1.3 Global Anti-Obesity Therapeutics Sales Market Share by Type (2018-2029)
4.2 Global Anti-Obesity Therapeutics Revenue by Type (2018-2029)
4.2.1 Global Anti-Obesity Therapeutics Revenue by Type (2018-2023)
4.2.2 Global Anti-Obesity Therapeutics Revenue by Type (2024-2029)
4.2.3 Global Anti-Obesity Therapeutics Revenue Market Share by Type (2018-2029)
4.3 Global Anti-Obesity Therapeutics Price by Type (2018-2029)
5 Segment by Application
5.1 Global Anti-Obesity Therapeutics Sales by Application (2018-2029)
5.1.1 Global Anti-Obesity Therapeutics Sales by Application (2018-2023)
5.1.2 Global Anti-Obesity Therapeutics Sales by Application (2024-2029)
5.1.3 Global Anti-Obesity Therapeutics Sales Market Share by Application (2018-2029)
5.2 Global Anti-Obesity Therapeutics Revenue by Application (2018-2029)
5.2.1 Global Anti-Obesity Therapeutics Revenue by Application (2018-2023)
5.2.2 Global Anti-Obesity Therapeutics Revenue by Application (2024-2029)
5.2.3 Global Anti-Obesity Therapeutics Revenue Market Share by Application (2018-2029)
5.3 Global Anti-Obesity Therapeutics Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Corporation Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bristol-Myers Squibb Anti-Obesity Therapeutics Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 Eisai Company
6.2.1 Eisai Company Corporation Information
6.2.2 Eisai Company Description and Business Overview
6.2.3 Eisai Company Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Eisai Company Anti-Obesity Therapeutics Product Portfolio
6.2.5 Eisai Company Recent Developments/Updates
6.3 FlaxoSithKline plc.
6.3.1 FlaxoSithKline plc. Corporation Information
6.3.2 FlaxoSithKline plc. Description and Business Overview
6.3.3 FlaxoSithKline plc. Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.3.4 FlaxoSithKline plc. Anti-Obesity Therapeutics Product Portfolio
6.3.5 FlaxoSithKline plc. Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novo Nordisk Anti-Obesity Therapeutics Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Alizyme
6.5.1 Alizyme Corporation Information
6.5.2 Alizyme Description and Business Overview
6.5.3 Alizyme Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Alizyme Anti-Obesity Therapeutics Product Portfolio
6.5.5 Alizyme Recent Developments/Updates
6.6 BoehringerIngelheim GmbH
6.6.1 BoehringerIngelheim GmbH Corporation Information
6.6.2 BoehringerIngelheim GmbH Description and Business Overview
6.6.3 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.6.4 BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product Portfolio
6.6.5 BoehringerIngelheim GmbH Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Anti-Obesity Therapeutics Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Takeda Pharmaceutical
6.8.1 Takeda Pharmaceutical Corporation Information
6.8.2 Takeda Pharmaceutical Description and Business Overview
6.8.3 Takeda Pharmaceutical Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Takeda Pharmaceutical Anti-Obesity Therapeutics Product Portfolio
6.8.5 Takeda Pharmaceutical Recent Developments/Updates
6.9 Rhythm Pharmaceuticals
6.9.1 Rhythm Pharmaceuticals Corporation Information
6.9.2 Rhythm Pharmaceuticals Description and Business Overview
6.9.3 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product Portfolio
6.9.5 Rhythm Pharmaceuticals Recent Developments/Updates
6.10 Shionogi USA
6.10.1 Shionogi USA Corporation Information
6.10.2 Shionogi USA Description and Business Overview
6.10.3 Shionogi USA Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Shionogi USA Anti-Obesity Therapeutics Product Portfolio
6.10.5 Shionogi USA Recent Developments/Updates
6.11 Vivus
6.11.1 Vivus Corporation Information
6.11.2 Vivus Anti-Obesity Therapeutics Description and Business Overview
6.11.3 Vivus Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Vivus Anti-Obesity Therapeutics Product Portfolio
6.11.5 Vivus Recent Developments/Updates
6.12 Zafgen
6.12.1 Zafgen Corporation Information
6.12.2 Zafgen Anti-Obesity Therapeutics Description and Business Overview
6.12.3 Zafgen Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Zafgen Anti-Obesity Therapeutics Product Portfolio
6.12.5 Zafgen Recent Developments/Updates
6.13 Norgine Pharmaceuticals Ltd.
6.13.1 Norgine Pharmaceuticals Ltd. Corporation Information
6.13.2 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Description and Business Overview
6.13.3 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product Portfolio
6.13.5 Norgine Pharmaceuticals Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-Obesity Therapeutics Industry Chain Analysis
7.2 Anti-Obesity Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-Obesity Therapeutics Production Mode & Process
7.4 Anti-Obesity Therapeutics Sales and Marketing
7.4.1 Anti-Obesity Therapeutics Sales Channels
7.4.2 Anti-Obesity Therapeutics Distributors
7.5 Anti-Obesity Therapeutics Customers
8 Anti-Obesity Therapeutics Market Dynamics
8.1 Anti-Obesity Therapeutics Industry Trends
8.2 Anti-Obesity Therapeutics Market Drivers
8.3 Anti-Obesity Therapeutics Market Challenges
8.4 Anti-Obesity Therapeutics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Anti-Obesity Therapeutics Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global Anti-Obesity Therapeutics Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global Anti-Obesity Therapeutics Market Competitive Situation by Manufacturers in 2022
    Table 4. Global Anti-Obesity Therapeutics Sales (K Units) of Key Manufacturers (2018-2023)
    Table 5. Global Anti-Obesity Therapeutics Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global Anti-Obesity Therapeutics Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global Anti-Obesity Therapeutics Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market Anti-Obesity Therapeutics Average Price (USD/Unit) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of Anti-Obesity Therapeutics, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of Anti-Obesity Therapeutics, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Anti-Obesity Therapeutics, Product Type & Application
    Table 12. Global Key Manufacturers of Anti-Obesity Therapeutics, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Anti-Obesity Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Obesity Therapeutics as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Anti-Obesity Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global Anti-Obesity Therapeutics Sales by Region (2018-2023) & (K Units)
    Table 18. Global Anti-Obesity Therapeutics Sales Market Share by Region (2018-2023)
    Table 19. Global Anti-Obesity Therapeutics Sales by Region (2024-2029) & (K Units)
    Table 20. Global Anti-Obesity Therapeutics Sales Market Share by Region (2024-2029)
    Table 21. Global Anti-Obesity Therapeutics Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global Anti-Obesity Therapeutics Revenue Market Share by Region (2018-2023)
    Table 23. Global Anti-Obesity Therapeutics Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global Anti-Obesity Therapeutics Revenue Market Share by Region (2024-2029)
    Table 25. North America Anti-Obesity Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America Anti-Obesity Therapeutics Sales by Country (2018-2023) & (K Units)
    Table 27. North America Anti-Obesity Therapeutics Sales by Country (2024-2029) & (K Units)
    Table 28. North America Anti-Obesity Therapeutics Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America Anti-Obesity Therapeutics Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe Anti-Obesity Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe Anti-Obesity Therapeutics Sales by Country (2018-2023) & (K Units)
    Table 32. Europe Anti-Obesity Therapeutics Sales by Country (2024-2029) & (K Units)
    Table 33. Europe Anti-Obesity Therapeutics Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe Anti-Obesity Therapeutics Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific Anti-Obesity Therapeutics Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific Anti-Obesity Therapeutics Sales by Region (2018-2023) & (K Units)
    Table 37. Asia Pacific Anti-Obesity Therapeutics Sales by Region (2024-2029) & (K Units)
    Table 38. Asia Pacific Anti-Obesity Therapeutics Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific Anti-Obesity Therapeutics Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Anti-Obesity Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America Anti-Obesity Therapeutics Sales by Country (2018-2023) & (K Units)
    Table 42. Latin America Anti-Obesity Therapeutics Sales by Country (2024-2029) & (K Units)
    Table 43. Latin America Anti-Obesity Therapeutics Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Anti-Obesity Therapeutics Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Anti-Obesity Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa Anti-Obesity Therapeutics Sales by Country (2018-2023) & (K Units)
    Table 47. Middle East & Africa Anti-Obesity Therapeutics Sales by Country (2024-2029) & (K Units)
    Table 48. Middle East & Africa Anti-Obesity Therapeutics Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa Anti-Obesity Therapeutics Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global Anti-Obesity Therapeutics Sales (K Units) by Type (2018-2023)
    Table 51. Global Anti-Obesity Therapeutics Sales (K Units) by Type (2024-2029)
    Table 52. Global Anti-Obesity Therapeutics Sales Market Share by Type (2018-2023)
    Table 53. Global Anti-Obesity Therapeutics Sales Market Share by Type (2024-2029)
    Table 54. Global Anti-Obesity Therapeutics Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global Anti-Obesity Therapeutics Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global Anti-Obesity Therapeutics Revenue Market Share by Type (2018-2023)
    Table 57. Global Anti-Obesity Therapeutics Revenue Market Share by Type (2024-2029)
    Table 58. Global Anti-Obesity Therapeutics Price (USD/Unit) by Type (2018-2023)
    Table 59. Global Anti-Obesity Therapeutics Price (USD/Unit) by Type (2024-2029)
    Table 60. Global Anti-Obesity Therapeutics Sales (K Units) by Application (2018-2023)
    Table 61. Global Anti-Obesity Therapeutics Sales (K Units) by Application (2024-2029)
    Table 62. Global Anti-Obesity Therapeutics Sales Market Share by Application (2018-2023)
    Table 63. Global Anti-Obesity Therapeutics Sales Market Share by Application (2024-2029)
    Table 64. Global Anti-Obesity Therapeutics Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global Anti-Obesity Therapeutics Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global Anti-Obesity Therapeutics Revenue Market Share by Application (2018-2023)
    Table 67. Global Anti-Obesity Therapeutics Revenue Market Share by Application (2024-2029)
    Table 68. Global Anti-Obesity Therapeutics Price (USD/Unit) by Application (2018-2023)
    Table 69. Global Anti-Obesity Therapeutics Price (USD/Unit) by Application (2024-2029)
    Table 70. Bristol-Myers Squibb Corporation Information
    Table 71. Bristol-Myers Squibb Description and Business Overview
    Table 72. Bristol-Myers Squibb Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 73. Bristol-Myers Squibb Anti-Obesity Therapeutics Product
    Table 74. Bristol-Myers Squibb Recent Developments/Updates
    Table 75. Eisai Company Corporation Information
    Table 76. Eisai Company Description and Business Overview
    Table 77. Eisai Company Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 78. Eisai Company Anti-Obesity Therapeutics Product
    Table 79. Eisai Company Recent Developments/Updates
    Table 80. FlaxoSithKline plc. Corporation Information
    Table 81. FlaxoSithKline plc. Description and Business Overview
    Table 82. FlaxoSithKline plc. Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 83. FlaxoSithKline plc. Anti-Obesity Therapeutics Product
    Table 84. FlaxoSithKline plc. Recent Developments/Updates
    Table 85. Novo Nordisk Corporation Information
    Table 86. Novo Nordisk Description and Business Overview
    Table 87. Novo Nordisk Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 88. Novo Nordisk Anti-Obesity Therapeutics Product
    Table 89. Novo Nordisk Recent Developments/Updates
    Table 90. Alizyme Corporation Information
    Table 91. Alizyme Description and Business Overview
    Table 92. Alizyme Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 93. Alizyme Anti-Obesity Therapeutics Product
    Table 94. Alizyme Recent Developments/Updates
    Table 95. BoehringerIngelheim GmbH Corporation Information
    Table 96. BoehringerIngelheim GmbH Description and Business Overview
    Table 97. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 98. BoehringerIngelheim GmbH Anti-Obesity Therapeutics Product
    Table 99. BoehringerIngelheim GmbH Recent Developments/Updates
    Table 100. Pfizer Corporation Information
    Table 101. Pfizer Description and Business Overview
    Table 102. Pfizer Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 103. Pfizer Anti-Obesity Therapeutics Product
    Table 104. Pfizer Recent Developments/Updates
    Table 105. Takeda Pharmaceutical Corporation Information
    Table 106. Takeda Pharmaceutical Description and Business Overview
    Table 107. Takeda Pharmaceutical Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 108. Takeda Pharmaceutical Anti-Obesity Therapeutics Product
    Table 109. Takeda Pharmaceutical Recent Developments/Updates
    Table 110. Rhythm Pharmaceuticals Corporation Information
    Table 111. Rhythm Pharmaceuticals Description and Business Overview
    Table 112. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 113. Rhythm Pharmaceuticals Anti-Obesity Therapeutics Product
    Table 114. Rhythm Pharmaceuticals Recent Developments/Updates
    Table 115. Shionogi USA Corporation Information
    Table 116. Shionogi USA Description and Business Overview
    Table 117. Shionogi USA Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 118. Shionogi USA Anti-Obesity Therapeutics Product
    Table 119. Shionogi USA Recent Developments/Updates
    Table 120. Vivus Corporation Information
    Table 121. Vivus Description and Business Overview
    Table 122. Vivus Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 123. Vivus Anti-Obesity Therapeutics Product
    Table 124. Vivus Recent Developments/Updates
    Table 125. Zafgen Corporation Information
    Table 126. Zafgen Description and Business Overview
    Table 127. Zafgen Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 128. Zafgen Anti-Obesity Therapeutics Product
    Table 129. Zafgen Recent Developments/Updates
    Table 130. Norgine Pharmaceuticals Ltd. Corporation Information
    Table 131. Norgine Pharmaceuticals Ltd. Description and Business Overview
    Table 132. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 133. Norgine Pharmaceuticals Ltd. Anti-Obesity Therapeutics Product
    Table 134. Norgine Pharmaceuticals Ltd. Recent Developments/Updates
    Table 135. Key Raw Materials Lists
    Table 136. Raw Materials Key Suppliers Lists
    Table 137. Anti-Obesity Therapeutics Distributors List
    Table 138. Anti-Obesity Therapeutics Customers List
    Table 139. Anti-Obesity Therapeutics Market Trends
    Table 140. Anti-Obesity Therapeutics Market Drivers
    Table 141. Anti-Obesity Therapeutics Market Challenges
    Table 142. Anti-Obesity Therapeutics Market Restraints
    Table 143. Research Programs/Design for This Report
    Table 144. Key Data Information from Secondary Sources
    Table 145. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Anti-Obesity Therapeutics
    Figure 2. Global Anti-Obesity Therapeutics Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global Anti-Obesity Therapeutics Market Share by Type in 2022 & 2029
    Figure 4. Centrally Acting Anti-obesity Drugs Product Picture
    Figure 5. Peripherally Acting Anti-obesity Drugs Product Picture
    Figure 6. Global Anti-Obesity Therapeutics Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 7. Global Anti-Obesity Therapeutics Market Share by Application in 2022 & 2029
    Figure 8. Hospital Use
    Figure 9. Clinic Use
    Figure 10. Household
    Figure 11. Other
    Figure 12. Global Anti-Obesity Therapeutics Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 13. Global Anti-Obesity Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 14. Global Anti-Obesity Therapeutics Sales (2018-2029) & (K Units)
    Figure 15. Global Anti-Obesity Therapeutics Average Price (USD/Unit) & (2018-2029)
    Figure 16. Anti-Obesity Therapeutics Report Years Considered
    Figure 17. Anti-Obesity Therapeutics Sales Share by Manufacturers in 2022
    Figure 18. Global Anti-Obesity Therapeutics Revenue Share by Manufacturers in 2022
    Figure 19. The Global 5 and 10 Largest Anti-Obesity Therapeutics Players: Market Share by Revenue in 2022
    Figure 20. Anti-Obesity Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 21. Global Anti-Obesity Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 22. North America Anti-Obesity Therapeutics Sales Market Share by Country (2018-2029)
    Figure 23. North America Anti-Obesity Therapeutics Revenue Market Share by Country (2018-2029)
    Figure 24. U.S. Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 25. Canada Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 26. Europe Anti-Obesity Therapeutics Sales Market Share by Country (2018-2029)
    Figure 27. Europe Anti-Obesity Therapeutics Revenue Market Share by Country (2018-2029)
    Figure 28. Germany Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. France Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 30. U.K. Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 31. Italy Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 32. Russia Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. Asia Pacific Anti-Obesity Therapeutics Sales Market Share by Region (2018-2029)
    Figure 34. Asia Pacific Anti-Obesity Therapeutics Revenue Market Share by Region (2018-2029)
    Figure 35. China Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Japan Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 37. South Korea Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 38. India Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 39. Australia Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. Taiwan Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. Indonesia Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. Thailand Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Malaysia Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Philippines Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Latin America Anti-Obesity Therapeutics Sales Market Share by Country (2018-2029)
    Figure 46. Latin America Anti-Obesity Therapeutics Revenue Market Share by Country (2018-2029)
    Figure 47. Mexico Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Brazil Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 49. Argentina Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 50. Middle East & Africa Anti-Obesity Therapeutics Sales Market Share by Country (2018-2029)
    Figure 51. Middle East & Africa Anti-Obesity Therapeutics Revenue Market Share by Country (2018-2029)
    Figure 52. Turkey Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Saudi Arabia Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 54. U.A.E Anti-Obesity Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 55. Global Sales Market Share of Anti-Obesity Therapeutics by Type (2018-2029)
    Figure 56. Global Revenue Market Share of Anti-Obesity Therapeutics by Type (2018-2029)
    Figure 57. Global Anti-Obesity Therapeutics Price (USD/Unit) by Type (2018-2029)
    Figure 58. Global Sales Market Share of Anti-Obesity Therapeutics by Application (2018-2029)
    Figure 59. Global Revenue Market Share of Anti-Obesity Therapeutics by Application (2018-2029)
    Figure 60. Global Anti-Obesity Therapeutics Price (USD/Unit) by Application (2018-2029)
    Figure 61. Anti-Obesity Therapeutics Value Chain
    Figure 62. Anti-Obesity Therapeutics Production Process
    Figure 63. Channels of Distribution (Direct Vs Distribution)
    Figure 64. Distributors Profiles
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS